Localization and differential activity of P-glycoprotein in the bovine olfactory and nasal respiratory mucosae

被引:46
作者
Kandimalla, KK [1 ]
Donovan, MD [1 ]
机构
[1] Univ Iowa, Coll Pharm, Iowa City, IA 52242 USA
关键词
CNS; efflux; etoposide; membrane transport proteins; nasal respiratory mucosa; nose-brain transport; olfactory mucosa; P-glycoprotein;
D O I
10.1007/s11095-005-5420-3
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. The purpose of this study was to demonstrate that P-glycoprotein (P-gp) is localized in the olfactory mucosa and is capable of limiting the nose-to-brain transport of substrates. Bovine olfactory and nasal respiratory mucosae were compared to both localize P-gp and to measure its activity within the epithelia. Methods. Immunolocalization was performed on the bovine olfactory and nasal respiratory mucosa using the C219 monoclonal antibody. Flux of etoposide, a substrate reported to be primarily effluxed by P-gp, across bovine olfactory and nasal respiratory mucosae was measured using Sweetana-Grass (Navicyte(R)) vertical diffusion cells. Experiments were performed to evaluate the effect of directionality, donor concentration, and the presence of inhibitors. Results. Dense staining was observed on the apical surface of the ciliated epithelial cells and within the submucosal lymphatics/vasculature and mucosal glands of the bovine olfactory and nasal respiratory mucosae. Staining in the nasal respiratory epithelium was weak and patchy when compared to that observed in the olfactory mucosa. The secretory transport (J(s-m)) kinetics of etoposide in the olfactory (K-m = 260.5 mu M, V-max = 0.179 mu M/cm(2) min) and nasal respiratory (K-m = 46.9 mu M, V-max = 0.034 mu M/cm(2) min) mucosae were observed to be saturable and concentration-dependent. The flux of etoposide in the submucosal-mucosal (J(s-m)) direction was significantly greater than the flux in the mucosal-submucosal (J(m-s)) direction in both the olfactory and nasal respiratory mucosa. The efflux ratios (J(s-m)/J(m-s)) of etoposide across the olfactory and the nasal respiratory mucosae were 2.02 and 2.10, respectively. In the presence of inhibitors such as 2,4-dinitrophenol ( 1 mM) and quinidine ( 1 mM), etoposide showed an increase in J(m-s) and a decrease in J(s-m). The etoposide efflux was unaffected in the presence of a specific multiresistance associated protein 1 (MRP1) inhibitor (MK571) and methotrexate, a substrate for BCRP and MRP1-4. Conclusions. P-gp was localized in the epithelial cells, nasal glands, and the vascular endothelium of both the bovine olfactory and nasal respiratory mucosae, and the expressed P-gp was capable of effluxing a substrate such as etoposide. The K-m and V-max of etoposide efflux were higher in the olfactory mucosa compared to the nasal respiratory mucosa, and the expression of P-gp seems to be greater in the olfactory epithelium compared to the nasal respiratory epithelium based on the staining density observed using immunohistochemistry.
引用
收藏
页码:1121 / 1128
页数:8
相关论文
共 49 条
[1]   FINE-STRUCTURE OF THE VOMERONASAL AND SEPTAL OLFACTORY EPITHELIA AND OF GLANDULAR STRUCTURES [J].
ADAMS, DR .
MICROSCOPY RESEARCH AND TECHNIQUE, 1992, 23 (01) :86-97
[2]  
Allen JD, 2003, CANCER RES, V63, P1339
[3]   Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles:: Potential role for breast cancer resistance protein in clinical drug-drug interactions [J].
Breedveld, P ;
Zelcer, N ;
Pluim, D ;
Sönmezer, Ö ;
Tibben, MM ;
Beijnen, JH ;
Schinkel, AH ;
van Tellingen, O ;
Borst, P ;
Schellens, JHM .
CANCER RESEARCH, 2004, 64 (16) :5804-5811
[4]   Constitutive expression of P-glycoprotein in normal lung alveolar epithelium and functionality in primary alveolar epithelial cultures [J].
Campbell, L ;
Abulrob, ANG ;
Kandalaft, LE ;
Plummer, S ;
Hollins, AJ ;
Gibbs, A ;
Gumbleton, M .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 304 (01) :441-452
[5]  
Chen Xue-Qing, 1998, J Alzheimers Dis, V1, P35
[6]  
Chen ZS, 2002, CANCER RES, V62, P3144
[7]  
Chou KJ, 1997, BIOPHARM DRUG DISPOS, V18, P335, DOI 10.1002/(SICI)1099-081X(199705)18:4<335::AID-BDD22>3.0.CO
[8]  
2-W
[9]  
Chow HHS, 1999, J PHARM SCI, V88, P754
[10]  
Collett A, 1999, J PHARMACOL EXP THER, V288, P171